Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 16/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.52 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158362 | 0.81 | ALPL (0.54) | SLC22A12HSD17B1HSD17B2 | |
| SCHEMBL2158422 | 0.80 | ERAP1 (0.55) | PTPN2PTPN1PTPN5KDM1A | |
| SCHEMBL3769130 | 0.79 | SLC22A12 (0.70) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL2157783 | 0.79 | KMT2A (0.63) | PTPN2PTPN1PTPN5HSD17B2KDM1A | |
| SCHEMBL2157999 | 0.77 | PTK2B (0.47) | — | |
| SCHEMBL2158492 | 0.77 | USP2 (0.49) | — | |
| SCHEMBL2158080 | 0.77 | CNR1 (0.42) | SLC22A12HSD17B1HSD17B2 | |
| SCHEMBL2158687 | 0.77 | CNR1 (0.42) | PTPN2PTPN1PTPN5KDM1A | |
| SCHEMBL2157975 | 0.77 | HSD17B1 (0.45) | SLC22A12PTPN2PTPN1PTPN5HSD17B1 | |
| SCHEMBL2157528 | 0.75 | PFKFB3 (0.52) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | SLC22A12 2078/4885CYP2C9 1258/4885SLC22A6 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.